Eledon Pharmaceuticals Inc. held its Annual Meeting of Stockholders on June 10, 2025. The stockholders approved the election of Keith A. Katkin, Allan D. Kirk, M.D., Ph.D., FACS, and John S. McBride as Class II Directors. An amendment to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares was approved. An amendment to the Certificate of Incorporation to provide exculpation for certain officers was also approved. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.